Screener
CytomX Therapeutics CTMX CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Deferred revenue | 26,223 | (61,772) |
| Net cash used in operating activities | (43,617) | (36,796) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | — | (146) |
| Purchases of short-term investments | (311,824) | (128,618) |
| Maturities of short-term investments | 125,000 | 83,000 |
| Net cash used in investing activities | (186,824) | (45,764) |
| Cash flows from financing activities: |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's capex?
- CytomX Therapeutics (CTMX) reported capex of $0 in Q2 2026.
- How has CytomX Therapeutics's capex changed year-over-year?
- CytomX Therapeutics's capex decreased by 100.0% year-over-year, from $27K to $0.
- What is the long-term trend for CytomX Therapeutics's capex?
- Over 3 years (2021 to 2024), CytomX Therapeutics's capex has grown at a -42.2% compound annual growth rate (CAGR), from $1.61M to $310K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about CytomX Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude